Coste efectividad de la estrategia de cribado de citomegalovirus en recién nacidos mayores de 34 semanas de bajo peso para la edad gestacional / Cost-effectiveness of a cytomegalovirus screening strategy in neonates born after 34 weeks small for gestational age
An. pediatr. (2003. Ed. impr.)
; 98(1): 41-47, ene. 2023. ilus, tab
Article
in Spanish
| IBECS
| ID: ibc-214785
Responsible library:
ES1.1
Localization: ES15.1 - BNCS
RESUMEN
Introducción:
El citomegalovirus (CMV) es una de las infecciones congénitas más frecuentes, con una prevalencia del 0,3-2,4%. En España, al no formar parte del cribado gestacional, se realiza screening de los recién nacidos con factores de riesgo y, en muchos centros, de los que presentan bajo peso para la edad gestacional (BPEG). Para ello se realiza, generalmente, determinación de Polymerase Chain Reaction (PCR) del virus en orina y/o ecografía transfontanelar en busca de imágenes compatibles. El objetivo del estudio es evaluar el rendimiento de la PCR de CMV en orina y ecografía transfontanelar, en recién nacidos >34 semanas asintomáticos, sin factores de riesgo, con BPEG. El objetivo secundario es evaluar el coste-efectividad. Material ymétodos:
Estudio observacional, descriptivo y retrospectivo, entre enero y diciembre de 2019, en un hospital de tercer nivel (IIIC). Incluye recién nacidos >34 semanas, sin factores de riesgo con BPEG, con PCR de CMV en orina y/o ecografía transfontanelar realizada. (AU)ABSTRACT
Introduction:
Infection by cytomegalovirus (CMV) is one of the most common congenital infections, with a global prevalence of 0.3%-2.4%. In Spain, CMV screening is not performed during pregnancy, but rather in neonates with risk factors, and, in many hospitals, in those born small for gestational age (SGA). Screening is usually performed by measurement of the viral load in urine by polymerase chain reaction (PCR) and/or head ultrasound in search of compatible features. The aim of the study was to assess the yield of the CMV PCR test in urine and head ultrasound examination in asymptomatic neonates born SGA after 34 weeks gestation. The secondary objective was to assess the cost-effectiveness of this strategy. Design andmethods:
We conducted an observational and retrospective study between January and December 2019 in a tertiary care hospital. It included neonates delivered after 34 weeks, SGA and without additional risk factors assessed with a CMV PCR test in urine and/or head ultrasound. (AU)
Full text:
Available
Collection:
National databases
/
Spain
Database:
IBECS
Main subject:
Mass Screening
/
Cytomegalovirus
/
Neonatology
Limits:
Female
/
Humans
/
Male
/
Infant, Newborn
/
Pregnancy
Language:
Spanish
Journal:
An. pediatr. (2003. Ed. impr.)
Year:
2023
Document type:
Article
Institution/Affiliation country:
Hospital General Universitario Gregorio Marañón/España